Attached files
| file | filename |
|---|---|
| EX-21.1 - EXHIBIT 21.1 - IMMUNE PHARMACEUTICALS INC | v466981_ex21-1.htm |
| 10-K - FORM 10-K - IMMUNE PHARMACEUTICALS INC | v466981_10k.htm |
| EX-32.1 - EXHIBIT 32.1 - IMMUNE PHARMACEUTICALS INC | v466981_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - IMMUNE PHARMACEUTICALS INC | v466981_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - IMMUNE PHARMACEUTICALS INC | v466981_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - IMMUNE PHARMACEUTICALS INC | v466981_ex23-1.htm |
Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Immune Pharmaceuticals Inc. (the “Company”) on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Militello, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C § 1350, as adopted pursuant to § 906 of the Sarbanes –Oxley Act of 2002, that:
| 1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ John Militello | |
| John Militello | |
|
VP of Finance, Controller and Chief Accounting Officer (Principal Financial Officer and |
|
| May 17, 2017 |